Closed · RFA-CA-11-009 · CFDA 93.393;93.394;93.395;93.396 · Discretionary
Alliance of Glycobiologists for Detection of Cancer (U01)
Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.
- up to $350K
- Award range
- Closed
- Status
- October 7, 2011
- Close date
- -
- Expected awards
The verdict
Alliance of Glycobiologists for Detection of Cancer (U01) is a closed discretionary listing from National Institutes of Health that offered Up to $350,000. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 12,419 other opportunities from National Institutes of Health.
- up to $350K
- award range
- Closed
- application status
- 93.393;93.394;93.395;93.396
- CFDA program
- 12,419
- other opportunities from National Institutes of Health
Archived opportunity record
Alliance of Glycobiologists for Detection of… is closed (last close October 7, 2011). Check the agency catalog for replacement NOFOs. National Institutes of Health still indexes 12,419 other opportunities here.
According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.
Deadline tracker
Application window closed
Closed October 7, 2011
Est. Total Funding
$3,500,000
Instrument
Cooperative Agreement
Description
The purpose of this Funding Opportunity Announcement (FOA) is to continue support for the program referred to as the Alliance of Glycobiologists for Detection of Cancer (http://glycomics.cancer.gov). Through this FOA, the NCI solicits new and competing renewal applications for research projects to elucidate how changes in cellular carbohydrates may promote cancer initiation and progression and use this information to identify glycan-based abnormalities that have the potential to serve as biomarkers for early cancer detection or risk assessment. These changes may be studied at the level of glycoproteins, glycolipids, glycosaminoglycans, and/or their binding proteins. The proposed projects must also address the ability of these biomarker candidates to accurately distinguish individuals with cancer from those without. It is expected that the most promising biomarker candidates will ultimately be tested in clinical validation studies, although such validation studies are not required for the proposed projects. In addition to planning for the individual research projects, the applicants responding to this FOA must plan for the participation in trans-Alliance activities, including collaborative projects with other awardees.
Market-open applicant set · includes for-profit door
The eligibility set for Alliance of Glycobiologists for Detection of… includes a for-profit door among 8 printed types (State governments; Public / state-controlled institutions of higher education; Nonprofits with 501(c)(3) status (other than IHEs); Nonprofits without 501(c)(3) status (other than IHEs); +4 more). Competitive traffic can include commercial applicants alongside other listed classes. The extract does not mark applicant cost-sharing as required. Instrument: Cooperative Agreement. Funding-activity codes span Education · Health (ED;HL). Only 98 other National Institutes of Health listings share this exact eligibility-code string (1% of 12,420).
- Code 00
- State governments
- Code 06
- Public / state-controlled institutions of higher education
- Code 12
- Nonprofits with 501(c)(3) status (other than IHEs)
- Code 13
- Nonprofits without 501(c)(3) status (other than IHEs)
- Code 20
- Private institutions of higher education
- Code 22
- For-profit organizations other than small businesses
- Code 23
- Small businesses
- Code 25
- Others (see official listing text)
Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
More from National Institutes of Health
Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed)
Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed)
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)
Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)
What to do next
Alliance of Glycobiologists for Detection of… is closed; use the parent program and agency catalog for the next funding cycle.
- Browse open federal opportunities in the same category when this listing is closed. Open opportunities
- Look up CFDA 93.393;93.394;93.395;93.396 across all indexed listings before you commit to this opportunity alone. Eligibility finder
- National Institutes of Health lists 12,419 other indexed opportunities on PlainGrants. Agency catalog
Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |